You are here: Industry Insights > Deloitte

News List

The Pharmaceutical Industry is Proving its Resilience Amid the COVID-19 Pandemic Deborah Seah
May 31, 2021
In the past year, the pharmaceutical industry has been in the limelight amid the COVID-19 pandemic.
Deloitte: Holiday Travel Cleared for Take Off, but COVID-19 Continues to Impact the Journey prnewswire
November 04, 2021
After more than a year and half of the pandemic, the holiday travel season will get a strong start with 3 in 10 of all trips Americans plan to take slated for Thanksgiving.
'Hearts of Athletes' Research Study Launches to Understand Effects of COVID-19 Using Innovative Digital Platform From Deloitte With Support From the Joel Cornette Foundation prnewswire
August 10, 2021
The Hearts of Athletes study which has generous support from The Joel Cornette Foundation, is now open and recruiting participants at the Duke Heart Center.
Deloitte 2021 Quality Engineering Report: Emerging Technology Driving QE to a Top Priority for Enterprises prnewswire
June 25, 2021
A new Deloitte report found that those who embrace quality engineering (QE) as a catalyst for speed, agility and business performance will be better positioned in a highly competitive, fast-paced market in the future.
Deloitte finds Pharma returns on R&D reach new low europeanpharmaceuticalreview
April 16, 2019
Deloitte finds Pharma returns on R&D reach new low.
Deloitte finds Pharma returns on R&D reach new low europeanpharmaceuticalreview
January 04, 2019
Deloitte has found a sharp decline in the returns on investment from top pharmaceutical companies, with returns at almost half of what they were in 2010
R&D returns fall to lowest level in nine years: Deloitte, GlobalData biospectrumasia
December 26, 2018
‘Unlocking R&D productivity: Measuring the return from pharmaceutical innovation 2018’ published by Deloitte, reveals that returns are down 1.8 percentage points from 3.7 per cent in 2017, and forecast average peak sale.
Pharma R&D productivity hits new low amid rising costs pharmaphorum
December 20, 2018
Returns on pharma R&D investment are at a nine-year low, and the cost of developing a drug has nearly doubled since 2010, according to Deloitte’s yearly assessment of the industry’s pipeline productivity.
Deloitte: Multinational Pharmaceutical Enterprises are in Deep Waters in China en-cphi.cn
April 28, 2017
Deloitte has recently issued a report New Healthcare Reform in a New Era--Challenges for Multinational Pharmaceutical Companies and Corresponding Countermeasures to be taken to analyze the 5 challenges of multinational pharmaceutical companies in China.